Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
31.14 EUR | +0.55% |
|
+2.37% | -10.14% |
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- One of the major weak points of the company is its financial situation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.14% | 17.21B | - | ||
-5.81% | 180B | C+ | ||
-1.63% | 106B | C | ||
-4.14% | 67.55B | A | ||
-6.56% | 46.11B | B- | ||
+13.22% | 45.79B | B- | ||
+6.13% | 41.61B | B+ | ||
+19.93% | 31.07B | B | ||
+13.61% | 24.77B | A- | ||
-5.36% | 24.27B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BAX Stock
- BTL Stock
- Ratings Baxter International Inc.